Neil Kumar Credit: Endpoints

Bridge­Bio CEO Neil Ku­mar en­gi­neers a deal to reel back Ei­dos shares. Or is he re­al­ly hunt­ing a buy­out?

A year af­ter Bridge­Bio took its biotech sub­sidiary Ei­dos pub­lic at $17 a share $EI­DX, the moth­er com­pa­ny wants it all back. 

Bri­an Stephen­son

Bridge­Bio CFO Bri­an Stephen­son alert­ed in­vestors in an SEC fil­ing late last week that the San Fran­cis­co-based com­pa­ny pro­posed to buy out the in­vestors who snapped up a third of the eq­ui­ty, shoot­ing for a stock-for-stock deal.

Bridge­Bio, an um­brel­la drug de­vel­op­ment group co-found­ed by CEO Neil Ku­mar which owns 66.6% of Ei­dos, went pub­lic in a record-set­ting IPO a few weeks ago, pric­ing at $17 a share — but now trad­ing north of $26, even af­ter a 10% trim on Fri­day as the news of the fil­ing be­gan to per­co­late.

In a re­lease out this morn­ing, Bridge­Bio is propos­ing a swap: 1.3 shares of Bridge­Bio for every share of Ei­dos it doesn’t own. 

That has SVB Leerink’s Mani Foroohar won­der­ing if the re­al goal here isn’t spurring a bet­ter buy­out of­fer, with a big up­side.

While these steps are in line with our ex­pec­ta­tions and the Board car­ry­ing out its fidu­cia­ry re­spon­si­bil­i­ties, we do see a sce­nario in which a po­ten­tial com­pet­i­tive “over­bid” for the com­pa­ny could yield up­side be­yond the ~21% im­plied un­af­fect­ed pre­mi­um from BBIO’s ini­tial of­fer. As the own­er of a ma­jor­i­ty of EI­DX shares, BBIO would ben­e­fit fi­nan­cial­ly in this sce­nario, though BBIO (in an An­nex to to­day’s EI­DX dis­clo­sure) pro­claims no in­ter­est in sell­ing con­trol of EI­DX to an­oth­er en­ti­ty.

For its part, Bridge­Bio is sell­ing the prospect of bet­ter di­ver­si­fi­ca­tion. Af­ter all, not­ed Stephen­son, Ei­dos in­vestors shouldn’t be wait­ing for a buy­out.

As stock­hold­ers of Bridge­Bio, the Com­pa­ny’s stock­hold­ers would have the op­por­tu­ni­ty to ben­e­fit from and par­tic­i­pate in con­tin­ued up­side in Ei­dos while di­ver­si­fy­ing their in­vest­ment through ex­po­sure to the broad port­fo­lio of as­sets be­ing de­vel­oped by Bridge­Bio. This may be im­por­tant to cur­rent in­vestors, es­pe­cial­ly giv­en the dearth of M&A in the car­dio­vas­cu­lar area there­by lim­it­ing op­por­tu­ni­ties for liq­uid­i­ty and di­ver­si­fi­ca­tion.

Bridge­Bio now has a big uni­corn val­u­a­tion of $3.24 bil­lion, com­pared to $1.3 bil­lion for Ei­dos, which closed Fri­day at $35.17.

A spe­cial com­mit­tee with RA Cap­i­tal’s Ra­jeev Shah and William Lis will be re­spon­si­ble for han­dling the buy­out. Shah, a high-pro­file fig­ure in the biotech fi­nance scene, led the $64 mil­lion round for Ei­dos in the spring of 2018, work­ing di­rect­ly with Ku­mar. Shah gam­bled on a mid-stage drug for TTR amy­loi­do­sis, look­ing to take the field against a well-ad­vanced slate of ri­vals from Pfiz­er, Al­ny­lam and Io­n­is.

Lis is the ex-CEO at Por­to­la.

Head­shot: Bri­an Stephen­son, Linkedin

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

FDA to Sarep­ta: Your wide­ly an­tic­i­pat­ed fol­lowup to Ex­ondys 51 is not get­ting an ac­cel­er­at­ed OK for Duchenne MD

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.